JCR Pharmaceuticals
Basic Information
- Stock Code
- 4552
- Industry
- Pharmaceuticals
- Category Detail
- Biotechnology & Pharmaceuticals
- Prefecture
- Hyogo Prefecture
- Establishment Year
- September 1975
- Listing Year
- October 1992
- Official Website
- https://www.jcrpharm.co.jp/
- TSE Information
- TSE Information
- Yahoo! Finance
- Yahoo! Finance
- Other Companies
- Adways, Kyowa Kirin, Takeda Pharmaceutical, Astellas Pharma, Sumitomo Pharma, Shionogi, Chugai Pharmaceutical, Eisai, Ono Pharmaceutical, Santen Pharmaceutical, Daiichi Sankyo, Otsuka Holdings, SanaBio
Overview
JCR Pharmaceuticals is a pharmaceutical manufacturer based in Hyogo Prefecture, founded in 1975, with strengths in gene recombination technology and biopharmaceutical development.
Current Situation
JCR Pharmaceuticals maintained solid performance in the fiscal year ending March 2024, with consolidated sales of 42.8 billion yen and operating profit of 7.5 billion yen. The company focuses on medical pharmaceuticals, with hormone preparations and regenerative medicine products as mainstays. It advances product development centered on bio-based products using gene recombination technology to meet domestic medical needs. It fulfilled a societal role in producing AstraZeneca's COVID-19 vaccine and is advancing overseas expansion. It strengthens market competitiveness through capital alliances with companies like Medipal Holdings. It possesses multiple R&D bases and manufacturing facilities in Kobe City, Hyogo Prefecture, focusing on stable supply of high-quality pharmaceuticals. Moving forward, it aims for technological innovation and business expansion in the biopharmaceutical field to contribute to a sustainable medical society.
Trivia
Interesting Facts
- Advanced company handling Japan's first allogeneic regenerative medicine product.
- Commissioned for domestic manufacturing of AstraZeneca's COVID-19 vaccine.
- Long-term accumulation of technology in recombinant hormone preparations.
- Multiple manufacturing and research bases consolidated in Kobe City, Hyogo Prefecture.
- Medipal Holdings, a major medical wholesaler, is a shareholder.
- Listed on JASDAQ in 1992, later transitioned to Tokyo Stock Exchange Prime.
- Diverse repertoire of manufacturing and marketing approvals, including rare disease drugs.
- Established investigational drug manufacturing center and cell processing center.
- Strong R&D system with active licensing of formulation development technology.
- Expanding collaborations with global partners in the 2020s.
Hidden Connections
- Capital and business alliance with Medipal Holdings for distribution network collaboration.
- Supported by Kissei Pharmaceutical as a major shareholder.
- Close cooperative relationship with AstraZeneca in COVID-19 vaccine production.
- Strong sales network shared with pharmaceutical wholesalers and domestic medical institutions.
- Deeply involved in Hyogo Prefecture Kobe City's bio industry cluster.
- Rich track record of joint research with university hospitals and public research institutions.
- Strength in domestic market with manufacturing and sales of enzyme preparations for rare diseases.
- Maintains facilities capable of integrated manufacturing from investigational drugs to commercial products.
Future Outlook
Growth Drivers
- Expansion of domestic and international markets for biopharmaceuticals and regenerative medicine
- Utilization of COVID-19 vaccine-related technology and production capacity
- Advancement of technological innovation in advanced recombinant formulations
- Strengthening strategic collaborations with domestic medical institutions and pharmaceutical companies
- Diversification of technology revenue through licensing business
- Expansion of investigational drug manufacturing market and increasing quality needs
- Improved cost competitiveness through production base efficiency
- Enhanced corporate value through proactive sustainability responses
Strategic Goals
- Aim to double biopharmaceutical sales
- Expand domestic market share for regenerative medicine products
- Build product supply system for overseas markets
- Establish environmentally low-impact and sustainable manufacturing
- Continuous investment in cutting-edge technology development
- Stabilize revenue through strengthened management foundation and diversification
Business Segments
Pharmaceutical Manufacturing Contract
- Overview
- Provides formulation and biopharmaceutical manufacturing services to pharmaceutical companies domestically and internationally.
- Competitiveness
- High-quality manufacturing enabled by advanced gene recombination technology
- Customers
-
- Domestic Pharmaceutical Companies
- Overseas Pharmaceutical Companies
- Biotech Ventures
- Public Research Institutions
- Products
-
- Formulation Manufacturing Outsourcing
- Vaccine Manufacturing Contract
- Cell Therapy Manufacturing
- Investigational Drug Manufacturing
Regenerative Medicine Product Development
- Overview
- Development and manufacturing of allogeneic cell products centered on regenerative medicine products.
- Competitiveness
- Japan's first approval track record and manufacturing facilities
- Customers
-
- Medical Institutions
- Regenerative Medicine Ventures
- Pharmaceutical Companies
- Clinical Trial Institutions
- Products
-
- Regenerative Medicine Products
- Stem Cell Manufacturing
- Cell Processing Services
Pharmaceutical Development Technology Licensing
- Overview
- Licensing of pharmaceutical formulation design and production technology.
- Competitiveness
- Accumulated expertise in recombinant hormone preparations
- Customers
-
- Pharmaceutical Companies
- Biotechnology Companies
- Research Institutions
- Products
-
- Pharmaceutical Formulation Technology
- Production Process Design
- Quality Control Technology
Investigational Drug Manufacturing
- Overview
- Specialized manufacturing and quality control of investigational drugs.
- Competitiveness
- High-quality investigational drug manufacturing facilities and expertise
- Customers
-
- Pharmaceutical Companies
- Clinical Trial Institutions
- CROs
- Products
-
- Investigational Formulations
- Investigational Materials
- Quality Assurance Services
Bio Research Center Services
- Overview
- Technology provision and services supporting research and development.
- Competitiveness
- Advanced bio technology research infrastructure
- Customers
-
- Academic Research Institutions
- Bio Companies
- Pharmaceutical Development Departments
- Products
-
- Gene Recombination Technology Support
- Cell Culture Services
- Research Reagent Sales
Logistics Services
- Overview
- Dedicated logistics services for strict pharmaceutical management.
- Competitiveness
- Temperature control technology specialized for quality maintenance
- Customers
-
- Pharmaceutical Companies
- Medical Institutions
- Wholesalers
- Products
-
- Pharmaceutical Storage
- Temperature-Controlled Delivery
- Logistics Management Systems
Competitive Advantage
Strengths
- Advanced accumulation of gene recombination technology
- Manufacturing technology specialized in biopharmaceuticals
- Multiple manufacturing bases in Hyogo Prefecture
- Strong alliance with AstraZeneca
- Pioneer in allogeneic regenerative medicine products in Japan
- Diverse lineup of medical pharmaceuticals
- Expansion of formulation development technology licensing business
- Solid management foundation based on capital alliances
- High-quality investigational drug manufacturing capabilities
- Reputation and trust in the pharmaceutical industry
Competitive Advantages
- Product differentiation through advanced recombinant hormone technology
- Precedence in approvals and manufacturing systems in regenerative medicine
- Collaboration strength with globally expanding AstraZeneca
- Broad customer needs coverage through diverse manufacturing contracts
- New treatment product development via proprietary cell processing technology
- Revenue securing through pharmaceutical development technology licensing
- Efficiency of concentrated research and manufacturing bases in Kobe City, Hyogo Prefecture
- Advanced quality control and investigational drug manufacturing know-how
- R&D promotion system leveraging public-private partnerships
- Risk diversification through diversified product portfolio
Threats
- Intense competition with major domestic and international pharmaceutical companies
- Risks of prolonged development and high costs in biopharmaceuticals
- Impacts from changes in new regulations and approval processes
- Revenue uncertainty due to changes in COVID-19 related markets
- Decline in market competitiveness if lagging in technological innovation
- Revenue reduction risk from product patent expirations
- Potential raw material cost increases due to exchange rate fluctuations
- Increased regulatory compliance burden in overseas markets
- Intensified competition for recruiting and retaining specialized talent
- Supply chain vulnerabilities
Innovations
2021: Domestic COVID-19 Vaccine Production Starts
- Overview
- Began domestic manufacturing of AstraZeneca's vaccine, achieving societal contribution.
- Impact
- Supported domestic supply with 90 million doses produced
2020: Temcell® HS Injection Approved for Regenerative Medicine
- Overview
- Obtained manufacturing and marketing approval for Japan's first allogeneic regenerative medicine product.
- Impact
- Became domestic leader in brain injury treatment field
2022: Growject® Liquid Preparation Manufacturing and Marketing Approval
- Overview
- Obtained approval for liquid formulation of recombinant human growth hormone preparation.
- Impact
- Improved patient convenience and market expansion
2023: Expansion of New Formulation Technology Licensing
- Overview
- Strengthened licensing of formulation manufacturing technology to other companies.
- Impact
- Contributed to diversification of technology revenue
Sustainability
- Energy-saving upgrades to manufacturing equipment to reduce environmental impact
- Contribution to social issues through regenerative medicine product development
- Promotion of local employment creation and diverse talent recruitment
- Reduction of pharmaceutical waste and promotion of recycling
- Expansion of CSR activities through collaboration with local communities
- Improvement in medical safety through strengthened quality control